Contact Us

Global Hyperphosphatemia Treatment Market Share Analysis 2025, Forecast To 2034

27 Feb, 2025

What Has Been the Progress and Growth of the Hyperphosphatemia Treatment Market in Recent Years?

The hyperphosphatemia treatment market has seen considerable growth due to a variety of factors.
• In recent times, there has been a swift expansion in the market size for hyperphosphatemia treatment. It is projected to surge from $4.56 billion in 2024 to $5.13 billion in 2025, marking a compound annual growth rate (CAGR) of 12.4%.
The notable growth during the historical period is due to factors such as the rising cases of chronic kidney disease (CKD), an increase in the elderly population, a high frequency of diabetes and hypertension, the growth of the patient population requiring dialysis, and advancements in medical research and the diagnosis of hyperphosphatemia.

What Can Be Expected from the Hyperphosphatemia Treatment Market in the Coming Years?

The hyperphosphatemia treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for hyperphosphatemia treatment is anticipated to experience quick expansion in the upcoming years, reaching $8.56 billion by 2029 with a compound annual growth rate (CAGR) of 13.7%.
The significant increase predicted for the forecast period can be connected to the escalation of lifestyle-related illnesses causing hyperphosphatemia, ongoing expansion in the aging population, heightened recognition and diagnosis of hyperphosphatemia, and the growth of emerging markets dealing with a high disease burden. Countries in development are witnessing a larger prescribing share of calcium-based phosphate binders. Key trends observed during the forecast period comprise evolutions in hyperphosphatemia treatment techniques, incorporation of telehealth and remote patient monitoring, joint efforts for research and development, concentration on patient learning and lifestyle management in hyperphosphatemia, and the creation of innovative phosphate binders and therapies.

What Are the Critical Driver Fuelling the Hyperphosphatemia Treatment Market's Growth?

The escalation in chronic illnesses amongst individuals is contributing significantly to the expansion of the hyperphosphatemia treatment market. These non-communicable diseases demand long-term therapeutic treatments. Chronic ailments include cardiovascular disorders, chronic kidney illness, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer, amongst others. For instance, as per the World Health Organization, a specialized United Nations branch based in Switzerland, it was reported in September 2023 that there were 41 million deaths. Of these, 74% was due to non-communicable diseases or chronic illnesses on a worldwide scale. Moreover, according to SingleCare Services LLC, a health savings platform in the US, there has been a surge in kidney diseases, leading each year approximately 1 million people to lose their lives owing to untreated kidney failure. Hyperphosphatemia is on the rise among patients suffering from end-stage renal disease. This raises the demand for hyperphosphatemia treatment or drugs in the market.

How Is the Hyperphosphatemia Treatment Market segmented?

The hyperphosphatemia treatment market covered in this report is segmented –
1) By Product: Sevelamer, Calcium-Based Phosphate Binders, Iron-Based Phosphate Binders, Lanthanum Carbonate, Other products
2) By Distribution channel: Hospital Pharmacy, Retail Pharmacy, Online stores Subsegments:
1) By Sevelamer: Sevelamer Hydrochloride, Sevelamer Carbonate
2) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
3) By Iron-Based Phosphate Binders: Ferric Citrate, Ferric Sulfate
4) By Lanthanum Carbonate: Lanthanum Carbonate Hydrate
5) By Other Products: Magnesium-Based Phosphate Binders, Novel Phosphate Binders

Pre-Book The Hyperphosphatemia Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:

What New Trends Are Influencing the Hyperphosphatemia Treatment Market?

The escalating activities in research and development signify a primary trend in the hyperphosphatemia treatment market. Firms operating in this sphere are honing their focus on research and development to devise innovative treatment methods for renal diseases and associated chronic conditions. For example, Eurostat, a European governmental agency, reported in April 2024 that the Ile-de-France region in France boasted the highest number of core human resources in science and technology in Europe at 2.4 million in 2023. The Comunidad de Madrid region in Spain followed closely with 1.2 million.

Who Are the Key Players in the Hyperphosphatemia Treatment Market?

Major companies operating in the hyperphosphatemia treatment market include:
• Sanofi SA
• Akebia Therapeutics Inc.
• Ardelyx Inc.
• Astellas Pharma Inc.
• Fresenius Medical Care AG & Co. KGaA
• Lupin Limited
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Ultragenyx Pharmaceutical Inc.
• Unicycive Therapeutics Inc.
• Vifor Pharma Management Ltd.
• Zeria Pharmaceutical Co. Ltd.
• Amgen Inc.
• AstraZeneca plc
• Baxter International Inc.
• Beckman Coulter Inc.
• Cleveland Clinic
• DaVita Inc.
• Kyowa Kirin Pharmaceuticals Co. Ltd.
• Mayo Clinic
• OPKO Health Inc.
• Tenet Healthcare Corporation
• UnitedHealth Group Inc.

What Is The Most Dominant Region In The Hyperphosphatemia Treatment Market?

North America was the largest region in the hyperphosphatemia treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperphosphatemia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa